177Lu-DOTA-2P(FAPI)2
/ Xiamen University
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
February 25, 2026
Fibroblast Activation Protein-Based Radio-Theranostics Attenuates Postinfarction Myocardial Fibrosis.
(PubMed, ACS Appl Mater Interfaces)
- "To enable precise diagnosis and intervention, we developed a FAP-dimer-based imaging/therapeutic platform using 68Ga-DOTA-2P(FAPI)2 for noninvasive visualization of fibroblast activation and its therapeutic analogue 177Lu-DOTA-2P(FAPI)2 for radionuclide therapy...No significant toxicity was observed within 7 days post-treatment. scRNA-seq revealed selective depletion of activated fibroblasts and suppression of pro-inflammatory signaling in the infarct border zone, confirming the antifibrotic mechanism."
Journal • Cardiovascular • Fibrosis • Immunology • Myocardial Infarction
May 11, 2025
FAP-targeted radioligand therapy with 68Ga/177Lu-DOTA-2P(FAPI)2 enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy
(SNMMI 2025)
- "Our findings indicated that FAP-targeting radiopharmaceuticals can induce DNA double-strand breaks and up-regulate PD-L1 expression, with 177Lu-DOTA-2P(FAPI)2 proving to be more effective than 68Ga-DOTA-2P(FAPI)2. Both 68Ga-DOTA-2P(FAPI)2 and 177Lu-DOTA-2P(FAPI)2 radiopharmaceuticals significantly improved therapeutic outcomes when combined with anti-PD-L1 monoclonal antibody (αPD-L1 mAb). Notably, the combination of 177Lu-DOTA-2P(FAPI)2 with αPD-L1 mAb immunotherapy eliminated tumors in mouse models."
Clinical • IO biomarker • Oncology • CD8 • FAP • FASLG
1 to 2
Of
2
Go to page
1